MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 164 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Phase III study of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial.
Mustapha Tehfé, Scot Dowden, Hagen F. Kennecke, Robert H. El-Maraghi, Bernard Lespérance, Félix Couture +4 more
2015· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations
affaboutunlabeled
Impact of intravenous cancer drug wastage on economic evaluations.
Judy Truong, Matthew C. Cheung, Helen Mai, Jessa Letargo, Alexandra Chambers, Mona Sabharwal +2 more
2017· article· en· Journal of Clinical Oncology· Immunology and Microbiology
machine prediction:candidate · metaresearchconsensus · none
0
citations
affunlabeled
Expression of mTOR in diffuse large B-cell lymphoma.
Srivalli Gopaluni, Neerja Vajpayee, Nancy Newman, Charu Thakral, Juhi Husain, Ajeet Gajra
2012· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Microrna-198: A novel tumor suppressor in prostate cancer.
Jessica Ray, Christianne Hoey, Xiaoyong Huang, Paul C. Boutros, Stanley K. Liu
2018· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.
Ugo De Giorgi, Arun Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Jae Young Joung +13 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About